{"entity":{"id":"nct04637763","kind":"trial","name":"CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)","aka":[],"tldr":"A phase 1 trial of Vispacabtagene regedleucel run by Caribou Biosciences, Inc., active and no longer recruiting.","summary":"CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) is a phase 1 interventional study registered as NCT04637763 by Caribou Biosciences, Inc., with 72 participants planned, started 2021-05-26. Conditions recorded: Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma and B Cell Non-Hodgkin's Lymphoma. Interventions recorded: CB-010, Cyclophosphamide and Fludarabine.","status":"active","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT04637763","url":"https://clinicaltrials.gov/study/NCT04637763"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["vispacabtagene-regedleucel"],"companies":["caribou"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04637763","phase":"1","setting":"A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)","sponsor":"Caribou Biosciences, Inc.","enrolled":72,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04637763/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"vispacabtagene-regedleucel","kind":"drug","name":"Vispacabtagene regedleucel","route":"/drugs/vispacabtagene-regedleucel/"}],"company":[{"id":"caribou","kind":"company","name":"Caribou Biosciences","route":"/companies/caribou/"}]}}